Codeine in Insurance Claims

Understanding codeine prescribing, regulatory changes, genetic factors, and what you need to assess in insurance claims.

Published: 3 April 2026 | Updated: 3 April 2026

What is Codeine?

Codeine is a weak opioid painkiller derived from opium. It's available in several formulations: as a single agent (typically 30-60 mg tablets), combined with paracetamol (commonly 8-500 mg or 30-500 mg combinations), or combined with ibuprofen. It's also found in cough suppressants and some antidiarrhoeal medications. Because codeine products are available over-the-counter in many formulations in both Australia and New Zealand, they're familiar to the public and widely prescribed in general practice.

In insurance claims, codeine appears frequently, particularly in workers compensation claims for minor to moderate pain. Its accessibility and familiarity make it ubiquitous, but this masks significant concerns about efficacy, adverse effects, and genetic variation that affect how claimants metabolise it.

Regulatory Changes: The Shifting Landscape

Australia

In February 2023, the TGA removed over-the-counter codeine. Products that previously didn't require prescription now require a doctor's prescription, bringing codeine more in line with other opioids. This reflects safety concerns about accessibility and uncontrolled use. The shift recognises that codeine's low efficacy (many patients don't respond well) combined with its misuse potential doesn't justify easy availability. For insurers, this means codeine should not be your default painkiller; it should be actively transitioned to safer, more effective alternatives.

New Zealand

New Zealand has also moved toward restricting codeine access. The regulatory environment is shifting toward evidence-based pain management that deprioritises codeine. This aligns with broader clinical guidelines emphasising non-opioid and non-pharmacological pain management.

Genetic Variation: The Metabolism Problem

Codeine's efficacy depends on an enzyme called CYP2D6, which converts codeine to morphine (the active metabolite responsible for pain relief). However, genetic variation means this conversion happens at very different rates in different people:

• Poor metabolisers (5-10 percent of populations): Have little or no functional CYP2D6. For these people, codeine is essentially inert. They take codeine expecting pain relief and get none, yet experience all the adverse effects. This is a wasted prescription.
• Intermediate metabolisers (30-40 percent): Have reduced enzyme function. Codeine works but only partially. They're better served by stronger opioids or non-opioid pain management.
• Normal metabolisers (50-60 percent): Codeine works reasonably well for pain relief.
• Ultra-rapid metabolisers (5-10 percent): Convert codeine to morphine very quickly. They're at risk of overdose and adverse effects at normal codeine doses.

Adverse Effects and Risks

Constipation

All opioids cause constipation, and codeine is no exception. In your claims, watch for claimants on prolonged codeine who develop severe constipation requiring laxatives. This reduces quality of life and can complicate other aspects of recovery.

Sedation and Impaired Cognition

Codeine causes drowsiness and impairs cognitive function. For a worker trying to return to work, codeine may hinder recovery more than help. If your claimant reports drowsiness or difficulty concentrating, codeine may be the culprit.

Dependence and Withdrawal

While codeine is weak, regular use (particularly codeine combinations with paracetamol) can lead to physical dependence. Many claimants find it difficult to stop codeine after months of use, even when no longer medically necessary. This prolongs disability.

Overuse Headaches

Codeine-containing combination products (particularly those with paracetamol) can cause medication-overuse headaches when used frequently. A claimant taking codeine-paracetamol several times weekly can develop rebound headaches, creating a cycle of increasing use and worsening headaches. This is common but often unrecognised.

When Should You Refer for Pharmacy Review?

Red Flags in Codeine Claims

• Codeine continued indefinitely for injury pain that should have largely resolved.
• Claimant reports worsening or new headaches despite codeine use (suggests medication-overuse headaches).
• Codeine-paracetamol used more than 2-3 times weekly.
• Claimant reports marked sedation or cognitive impairment attributed to codeine.
• Claimant reports inability to stop codeine despite wanting to (suggests dependence).
• Codeine combined with other CNS depressants at high doses.
• Prescriber lacks documented consideration of whether codeine is effective for this patient or whether alternatives are better.
• Claimant has documented poor response to codeine (pain unchanged despite use), yet prescription continues.

The Business Case for Codeine Deprescribing

From your insurer's perspective, codeine deprescribing makes financial and clinical sense. Codeine is cheap, but that's because it's marginally effective for many patients. The real cost is in prolonged disability: a claimant on ineffective codeine stays disabled longer; a claimant developing medication-overuse headaches requires escalated pain management; a claimant experiencing constipation and sedation has reduced functional recovery. Transitioning to better pain management approaches often costs less long-term and improves outcomes.

Transitions from Codeine

Unlike stronger opioids, codeine deprescribing is usually straightforward. Most claimants can simply cease codeine without tapering. Your pharmacist should recommend:

• Abrupt cessation of codeine (physical withdrawal is usually mild for codeine).
• Substitution with non-opioid pain management: paracetamol, NSAIDs (if not contraindicated), nerve pain agents (pregabalin, gabapentin) if neuropathic pain is present.
• Concurrent physiotherapy, occupational therapy, or pain psychology to manage pain without codeine.
• For claimants with medication-overuse headaches from codeine-paracetamol combinations, structured cessation followed by preventive strategies (e.g., prophylactic medications for headaches if appropriate).

Questions to Ask Your Pharmacist

1. Is codeine still justified given the time since injury and documented pain levels?
2. Is the claimant likely responding to codeine, or could they be a poor metaboliser with minimal benefit?
3. Are adverse effects (constipation, sedation, cognitive impairment) documented?
4. Is this a codeine-containing combination product, and is the combination justified?
5. Could the claimant transition to paracetamol or an NSAID alone and still achieve adequate pain control?
6. Are there signs of medication-overuse headaches or dependence?
7. What alternative pain management strategies are in place?
8. Can we develop a deprescribing plan with transition to safer alternatives?

Summary: Your Decision Framework

Codeine's role in insurance claims is diminishing. Regulatory changes in both Australia and New Zealand reflect its limited efficacy and unjustified risks. Genetic variation means a substantial proportion of claimants don't benefit from it. Many claimants on prolonged codeine can be transitioned to better pain management with concurrent non-pharmacological strategies. Rather than asking whether to approve codeine, ask whether your claimant still needs it and whether deprescribing to safer alternatives would improve outcomes. Your pharmacist can assess whether codeine is effective for this individual and recommend evidence-based transitions.